Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Assessing the role of CAR-T in CLL

David Maloney and Johannes Schetelig • 21 Sep 2019
iwCLL 2019
Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

David Maloney, MD, PhD, Fred Hutchinson Cancer Center, Seattle, and Johannes Schetelig, MD, WA, University of Dresden, Dresden, Germany, speaking at a roundtable discussion at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. The speakers elaborate on the future of CAR-T and cellular therapy in chronic lymphocytic leukemia (CLL), particularly as an alternative to allogeneic stem cell transplantation.

More from David Maloney

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022
4:36
Highlights from the immunotherapy in CLL session
David Maloney • 20 Sep 2021

More from Johannes Schetelig

6:30
Phase III ASAP trial results: role of remission induction chemotherapy before alloHCT in R/R AML
Johannes Schetelig • 10 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals